4kfz
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | + | ==Crystal structure of LMO2 and anti-LMO2 VH complex== | |
| - | === | + | <StructureSection load='4kfz' size='340' side='right' caption='[[4kfz]], [[Resolution|resolution]] 2.80Å' scene=''> |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[4kfz]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4KFZ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4KFZ FirstGlance]. <br> | |
| - | ==Disease== | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> |
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">LMO2, RBTN2, RBTNL1, RHOM2, TTG2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), Anti-LMO2 VH ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4kfz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4kfz OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4kfz RCSB], [http://www.ebi.ac.uk/pdbsum/4kfz PDBsum]</span></td></tr> | ||
| + | </table> | ||
| + | == Disease == | ||
[[http://www.uniprot.org/uniprot/RBTN2_HUMAN RBTN2_HUMAN]] A chromosomal aberration involving LMO2 may be a cause of a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(11,14)(p13;q11) with TCRD. | [[http://www.uniprot.org/uniprot/RBTN2_HUMAN RBTN2_HUMAN]] A chromosomal aberration involving LMO2 may be a cause of a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(11,14)(p13;q11) with TCRD. | ||
| - | + | == Function == | |
| - | ==Function== | + | |
[[http://www.uniprot.org/uniprot/RBTN2_HUMAN RBTN2_HUMAN]] Acts with TAL1/SCL to regulate red blood cell development. Also acts with LDB1 to maintain erythroid precursors in an immature state. | [[http://www.uniprot.org/uniprot/RBTN2_HUMAN RBTN2_HUMAN]] Acts with TAL1/SCL to regulate red blood cell development. Also acts with LDB1 to maintain erythroid precursors in an immature state. | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | LMO2 was discovered via chromosomal translocations in T-cell leukaemia and shown normally to be essential for haematopoiesis. LMO2 is made up of two LIM only domains (thus it is a LIM-only protein) and forms a bridge in a multi-protein complex. We have studied the mechanism of formation of this complex using a single domain antibody fragment that inhibits LMO2 by sequestering it in a non-functional form. The crystal structure of LMO2 with this antibody fragment has been solved revealing a conformational difference in the positioning and angle between the two LIM domains compared with its normal binding. This contortion occurs by bending at a central helical region of LMO2. This is a unique mechanism for inhibiting an intracellular protein function and the structural contusion implies a model in which newly synthesized, intrinsically disordered LMO2 binds to a partner protein nucleating further interactions and suggests approaches for therapeutic targeting of LMO2. | ||
| - | + | Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.,Sewell H, Tanaka T, Omari KE, Mancini EJ, Cruz A, Fernandez-Fuentes N, Chambers J, Rabbitts TH Sci Rep. 2014 Jan 10;4:3643. doi: 10.1038/srep03643. PMID:24407558<ref>PMID:24407558</ref> | |
| - | + | ||
| - | == | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |
| - | + | </div> | |
| - | [[Category: Chambers, J | + | == References == |
| - | [[Category: Cruz-Migoni, A | + | <references/> |
| - | [[Category: Fuentes-Fernandez, N | + | __TOC__ |
| - | [[Category: Mancini, E J | + | </StructureSection> |
| - | [[Category: Omari, K El | + | [[Category: Human]] |
| - | [[Category: Rabbitts, T H | + | [[Category: Chambers, J]] |
| - | [[Category: Sewell, H | + | [[Category: Cruz-Migoni, A]] |
| - | [[Category: Tanaka, T | + | [[Category: Fuentes-Fernandez, N]] |
| + | [[Category: Mancini, E J]] | ||
| + | [[Category: Omari, K El]] | ||
| + | [[Category: Rabbitts, T H]] | ||
| + | [[Category: Sewell, H]] | ||
| + | [[Category: Tanaka, T]] | ||
[[Category: Developmental protein]] | [[Category: Developmental protein]] | ||
[[Category: Lim domain]] | [[Category: Lim domain]] | ||
Revision as of 18:56, 21 December 2014
Crystal structure of LMO2 and anti-LMO2 VH complex
| |||||||||||
